![CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf](https://journals.sagepub.com/cms/10.1177/13524585211032803/asset/images/large/10.1177_13524585211032803-fig4.jpeg)
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
![Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS](https://www.pnas.org/cms/10.1073/pnas.1607843113/asset/7430ac92-470f-4cd9-922a-2a11367affbf/assets/graphic/pnas.1607843113fig01.jpeg)
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
![Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World](https://www.pharmaceuticalprocessingworld.com/wp-content/uploads/2019/09/active-biotech-logo.jpg)
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
![Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/8f1514b8-d153-42f6-ac7d-55bd0b7629c8/jnc13553-fig-0005-m.jpg)
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
![Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download](https://images.slideplayer.com/36/10609964/slides/slide_2.jpg)
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
![Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download](https://images.slideplayer.com/36/10609964/slides/slide_11.jpg)
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
![Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS](https://www.pnas.org/cms/10.1073/pnas.1607843113/asset/c2bd36ea-168a-4fda-bd3b-59eee654bfbc/assets/graphic/pnas.1607843113fig03.jpeg)